Bellerophon Therapeutics, Inc.

0.17 USD
+0.12 (+231.40%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Bellerophon Therapeutics, Inc. stock is up 185% since 30 days ago. The next earnings date is Apr 1, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 80% of the previous 9 March’s closed higher than February.

About Bellerophon Therapeutics, Inc.

Bellerophon Therapeutics, Inc. focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform. InOpulse is in Phase 3 clinical trial for the. treatment of pulmonary hypertension associated with fibrotic interstitial lung disease.